Abrignani Sergio

Chief Scientific Officer

T cell costimulation by the hepatitis C virus envelope protein E2 binding to CD81 is mediated by Lck.
Soldaini E, Wack A, D’Oro U, Nuti S, Ulivieri C, Baldari CT, Abrignani S.
Eur J Immunol. 2003 Feb;33(2):455-64.

Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection.
Masciopinto F, Freer G, Burgio VL, Levy S, Galli-Stampino L, Bendinelli M, Houghton M, Abrignani S, Uematsu Y.
Virology. 2002 Dec 20;304(2):187-96.

Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7.
Seo MY, Abrignani S, Houghton M, Han JH.
J Virol. 2003 Jan;77(1):810-2.

Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein.
Crotta S, Stilla A, Wack A, D’Andrea A, Nuti S, D’Oro U, Mosca M, Filliponi F, Brunetto RM, Bonino F, Abrignani S, Valiante NM.
J Exp Med. 2002 Jan 7;195(1):35-41.

Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines.
Falugi F, Petracca R, Mariani M, Luzzi E, Mancianti S, Carinci V, Melli ML, Finco O, Wack A, Di Tommaso A, De Magistris MT, Costantino P, Del Giudice G, Abrignani S, Rappuoli R, Grandi G.
Eur J Immunol. 2001 Dec;31(12):3816-24.

Folding of hepatitis C virus E1 glycoprotein in a cell-free system.
Merola M, Brazzoli M, Cocchiarella F, Heile JM, Helenius A, Weiner AJ, Houghton M, Abrignani S.
J Virol. 2001 Nov;75(22):11205-17.

The small extracellular loop of CD81 is necessary for optimal surface expression of the large loop, a putative HCV receptor.
Masciopinto F, Campagnoli S, Abrignani S, Uematsu Y, Pileri P.
Virus Res. 2001 Nov 28;80(1-2):1-10.

Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs.
Burioni R, Bugli F, Mancini N, Rosa D, Di Campli C, Moroncini G, Manzin A, Abrignani S, Varaldo PE, Clementi M, Fadda G.
Virology. 2001 Sep 15;288(1):29-35.

Vdelta1 T lymphocytes expressing a Th1 phenotype are the major gammadelta T cell subset infiltrating the liver of HCV-infected persons.
Agrati C, D’Offizi G, Narciso P, Abrignani S, Ippolito G, Colizzi V, Poccia F.
Mol Med. 2001 Jan;7(1):11-9.

Prospects for a hepatitis C virus vaccine.
Hsu HH, Abrignani S, Houghton M.
Clin Liver Dis. 1999 Nov;3(4):901-15. Review.

Virus-specific CD8(+) T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection.
Prezzi C, Casciaro MA, Francavilla V, Schiaffella E, Finocchi L, Chircu LV, Bruno G, Sette A, Abrignani S, Barnaba V.
Eur J Immunol. 2001 Mar;31(3):894-906.

CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs.
Kitadokoro K, Bordo D, Galli G, Petracca R, Falugi F, Abrignani S, Grandi G, Bolognesi M.
EMBO J. 2001 Jan 15;20(1-2):12-8.

Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells.
Wack A, Soldaini E, Tseng C, Nuti S, Klimpel G, Abrignani S.
Eur J Immunol. 2001 Jan;31(1):166-75.

Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.
Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P, Abrignani S, Foung SK.
J Virol. 2000 Nov;74(22):10407-16.

Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81.
Allander T, Drakenberg K, Beyene A, Rosa D, Abrignani S, Houghton M, Widell A, Grillner L, Persson MA.
J Gen Virol. 2000 Oct;81(Pt 10):2451-9.

INGM researches are supported by